Adenovirus p53 gene therapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 1, 2006, Pages 55-61

  Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenovirus; Apoptosis; Gene therapy; p53; Tumour suppression

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLINE; DEATH RECEPTOR; DNA; DOCETAXEL; DOXORUBICIN; FAS ANTIGEN; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN BAK; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETROVIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SAFETY; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

ADENOVIRIDAE;

EID: 30044439886     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.1.55     Document Type: Review

References (57)

1. BURNS T, EL-DEIRY W: The p53 pathway and apoptosis. J. Cell. Physiol. (1999) 181(15):231-239.
2. FUJIWARA T, GRIMM EA, MUKHOPADHYAY T et al.: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. (1993) 53(15):4129-4133.
3. RAYCROFT L, WU H, LOZANO G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 249(15):1049-1051.
4. ADAMS JM, CORY S: The Bcl-2 protein family: arbiters of cell survival. Science (1998) 281(15):1322-1326.
5. KAMIJO T, ZINDY F, ROUSSEL MF et al.: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 91(15):649-659.
6. ISOBE T, HIYAMA K, YOSHIDA Y, FUJIWARA Y, YAMAKIDO M: Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res. (1994) 85(15):1240-1246.
7. QUINLAN DC, DAVIDSON AG, SUMMERS CL, WARDEN HE, DOSHI HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. (1992) 52(15):4828-4831.
8. MARTIN HM, FILIPE MI, MORRIS RW, LANE DP, SILVESTRE F: p53 expression and prognosis in gastric carcinoma. Int. J. Cancer (1992) 50(15):859-862.
9. CAI DW, MUKHOPADHYAY T, ROTH JA: Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther. (1995) 2(15):199-205.
10. FUJIWARA T, CAI DW, GEORGES RN et al.: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model (Commentary). J. Natl. Cancer Inst. (1994) 86(15):1437-1438.
11. ZHANG WW, FANG X, MAZUR W et al.: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. (1994) 1(15):5-13.
12. WANG JX, BUCANA CD, ROTH JA, ZHANG WW: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther. (1995) 2(15):9-17.
13. GEORGES RN, MUKHOPADHYAY T, ZHANG Y, YEN N, ROTH JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. (1993) 53(15):1743-1746.
14. SPITZ FR, NGUYEN D, SKIBBER JM et al.: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. (1996) 2(15):1665-1671.
15. NIELSEN LL, DELL J, MAXWELL E et al.: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. (1997) 4(15):129-138.
16. BOUVET M, FANG B, EKMEKCIOGLU S et al.: Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. (1998) 5(15):189-195.
17. XU M, KUMAR D, SRINIVAS S et al.: Patenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther. (1997) 8(15):177-185.
18. CUSACK JC, SPITZ FR, NGUYEN D et al.: High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. (1996) 3(15):245-249.
19. MIYASHITA T, REED JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell (1995) 80(15):293-299.
20. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 265(15):1582-1584.
21. MOLINIER-FRENKEL V, LE BOULAIRE C, LE GAL FA et al.: Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum. Gene Ther. (2000) 11(15):1911-1920.
22. YEN N, IOANNIDES CG, XU K et al.: Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumor injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Ther. (2000) 7(15):530-536.
23. CARROLL JL, NIELSEN LL, PRUETT SB, MATHIS JM: The role of natural killer cells in adenovirus-mediated p53 gene therapy. Mol. Cancer Ther. (2001) 1(15):49-60.
24. OWEN-SCHAUB LB, ZHANG W, CUSACK JC et al.: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. (1995) 15(15):3032-3040.
25. ROTH JA, NGUYEN D, LAWRENCE DD et al.: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. (1996) 2(15):985-991.
26. ROTH JA: Clinical protocol: modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum. Gene Ther. (1996) 7(15):875-889.
27. ROTH JA: Clinical protocol: modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum. Gene Ther. (1996) 7(15):1013-1030.
28. SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst. (1999) 91(15):763-771.
29. CLAYMAN GL, EL-NAGGAR AK, LIPPMAN SM et al.: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. (1998) 16(15):2221-2232.
30. GOODWIN WJ, ESSER D, CLAYMAN GL et al.: Randomized Phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. (1999) 19(15):445a.
31. BIER-LANING CM, VANECHO D, YVERA, DREILING LK: A Phase II multi-center study of AD5CMV-P53 administered intratumorally to patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18(15):444a.
32. YVER A, DREILING LK, MOHANTY S et al.: Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in Phase I and II studies world-wide. Proc. Am. Soc. Clin. Oncol. (1999) 19(15):460a.
33. YONISH-ROUACH E, RESNITZKY D, LOTEM J et al.: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (1991) 352(15):345-347.
34. RAMQVIST T, MAGNUSSON KP, WANG Y, SZEKELEY L, KLEIN G: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene (1993) 8(15):1495-1500.
35. SHAW P, BOVEY R, TARDY S et al.: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA (1992) 89(15):4495-4499.
36. DEWEY WC, LING CC, MEYN RE: Radiation induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (1995) 33(15):781-796.
37. ROTH JA: Review: Clinical protocol for modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum. Gene Ther. (1995) 6(15):252-255.
38. MEYN RE, STEPHENS LC, HUNTER NR, MILAS L: Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs (1995) 6(3):443-450.
39. FUJIWARA T, GRIMM EA, MUKHOPADHYAY T et al.: Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res. (1994) 54(15):2287-2291.
40. NGUYEN DM, SPITZ FR, YEN N, CRISTIANO RJ, ROTH JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg. (1996) 112(15):1372-1377.
41. HAMADA M, FUJIWARA T, HIZUTA A et al.: The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol. (1996) 122(15):360-365.
42. NGUYEN DM, WIEHLE SA, KOCH PE et al.: Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. (1997) 4(15):191-198.
43. JASTY R, LU J, IRWIN T et al.: Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol. Genet. Metab. (1998) 65(15):155-164.
44. AKIMOTO T, HUNTER NR, BUCHMILLER L et al.: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. (1999) 5(15):2884-2890.
45. FEINMESSER M, HALPERN M, FENIG E et al.: Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum. Pathol. (1994) 30(15):1367-1372.
46. BROADDUS WC, LIU Y, STEELE LL et al.: Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J. Neurosurg. (1999) 91(15):997-1004.
47. SAKAKURA C, SWEENEY EA, SHIRAHAMA T et al.: Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer (1996) 67(15):101-105.
48. BRACHMAN DG, BECKET M, GRAVES D et al.: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cells lines. Cancer Res. (1993) 53(15):3667-3669.
49. SLICHENMYER WJ, NELSON WG, SLEBOS RJ, KASTAN MB: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. (1993) 53(15):4164-4168.
50. DANIELSEN T, SMITH-SORENSEN B, GRONLUND HA et al.: No association between radiosensitivity and TP53 status, G(1) arrest or protein levels of p53, myc, ras or raf in human melanoma lines. Int. J. Radiat. Biol. (1994) 75(15):1149-1160.
51. NEMUNAITIS J, SWISHER SG, TIMMONS T et al.: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. (2000) 18(15):609-622.
52. SCHULER M, HERRMANN R, DE GREVE JL et al.: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol. (2001) 19(15):1750-1758.
53. BULLER RE, RUNNEBAUM IB, KARLAN BY et al.: A Phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. (2002) 9(15):553-566.
54. BULLER RE, SHAHIN MS, HOROWITZ JA et al.: Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. (2002) 9(15):567-572.
55. SWISHER SG, ROTH JA, KOMAKI R et al.: Induction of p53 regulated genes and tumor regression in lung cancer following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy. Clin. Cancer Res. (2003) 9(15):93-101.
56. PENG Z, HAN D, ZHANG S et al.: Clinical evaluation of safety and efficacy of intratumoral administration of a recombinant adenoviral-p53 anticancer agent (Genkaxin®). Mol. Ther. (2003) 7(15):422-423.
57. RAMESH R, SAEKI T, TEMPLETON NS et al.: Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol. Ther. (2001) 3(15):337-350.